E133: Obinutuzumab for SLE (ALLEGORY)
From The Evidence Based Rheumatology Podcast by Michael Putman
March 19, 2026 · 15 min · Episode 134
About this episode
This episode discusses a randomized controlled trial investigating obinutuzumab for systemic lupus erythematosus (SLE).
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150 Landing Page: https://ebrheum.com/ Substack: https://autoimmunedevreport.substack.com/
People in this episode
Host: Michael Putman
Topics covered
- rheumatology
- clinical trials
- SLE
- obinutuzumab
- B cell inhibitors
Keywords
- obinutuzumab
- SLE
- B cell inhibitor
- RCT
- rheumatology
Mentioned in this episode
Organizations: NEJM, Substack
Products: obinutuzumab
Books & works: ALLEGORY
More episodes of The Evidence Based Rheumatology Podcast
- E135: IL17 and a GLP1? · April 30, 2026 · 11 min
- E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
- E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
- E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
- E130: Telitacicept for SLE · December 22, 2025 · 13 min
- E129: Long Term Routine Laboratory Monitoring in RA · December 4, 2025 · 15 min
Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.